Clinical Trial Details
— Status: Active, not recruiting
Administrative data
| NCT number |
NCT04895540 |
| Other study ID # |
SKIMSCL-2021-001 |
| Secondary ID |
|
| Status |
Active, not recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
April 10, 2021 |
| Est. completion date |
May 1, 2022 |
Study information
| Verified date |
May 2021 |
| Source |
Sheri Kashmir Institute of Medical Sciences |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational [Patient Registry]
|
Clinical Trial Summary
Arrhythmogenic Cardiomyopathy (ACM) is increasingly identified as an important cause of
cardiac morbidity and mortality, especially of SCD, in a younger population.
Although there are no epidemiological data available, the investigators' experience is that
in the North Indian region, ACM is rare outside our regions. ACM is also an understudied
cardiac disorder in the South-Asian region.
An ethnic nonmigratory population inhabits the two regions, and consanguineous marriages are
common. Based on these observations, the investigators firmly believe that there may be a
founder gene in our populations responsible for the increased incidence of ACM.
Our project includes a thorough phenotypic analysis ((ECG, Holter, and echocardiography) in
the ACM patients and their first-degree relatives; cardiac MRI and high resolution
endocardial bipolar and unipolar voltage mapping (using HD grid catheter) in the patients.
The patient provided blood for the extraction of DNA will first undergo target panel
sequencing for 20 known classic right-dominant ACM and left-dominant ACM. If this is negative
for known pathogenic and likely pathogenic variants but identified novel variants of
uncertain significance (VUS), then co-segregation analysis in family members will be
performed. This technique can provide helpful information to reclassify VUSs. If both these
are negative, then whole-exome 'trio' analysis will be performed, whch includes the proband
and two family members, to triangulate from all 20,000 genes to a list of candidates for
further interrogation.
The investigators wish to provide comprehensive answers to the research question by combining
the genetic analysis with phenotypic evaluation.
Description:
Arrhythmogenic Cardiomyopathy (ACM) is an inherited cardiomyopathy characterized by
structural and functional abnormalities in the right ventricle (and left ventricle, in 50%)
resulting in ventricular arrhythmias.1 It is an important cause of sudden cardiac death (SCD)
in young adults, accounting for 11% of all cases.2 The hallmark lesion of ACM is replacement
of the ventricular myocardium by fibrofatty tissue. 3ARVC is most often familial, with
autosomal dominant inheritance, autosomal recessive inheritance being uncommon. However, in
relatively isolated populations, autosomal recessive forms are recognized and often have more
severe phenotype. In fact, the first two genes discovered for ARVC were Naxos and Carvajal
syndromes, in isolated populations of Naxos Island and Equadorian populations respectively.
The genes involved in the pathogenesis of ACM are most often desmosomal genes like
plakoglobin (JUP), desmoplakin (DSP), plakophilin-2 (PKP2), desmoglein-2 (DSG2),
desmocollin-2 (DSC2). PKP2 mutations are the most common. However, there are disease-causing
genes that cause "classic" right ventricular ACM that do not encode for desmosomal proteins.4
The term "ALVC" has been proposed to recognize ACM of LV origin as distinct from right
ventricular ACM in which there is predominantly LV arrhythmia and structural abnormalities.4
The most common clinical presentation consists of ventricular arrhythmias and related
symptoms/events, which include palpitations, syncopal episodes (mostly occurring during
physical exercise), and cardiac arrest. The diagnosis of biventricular or predominant left AC
may be missed at the onset of symptoms in some patients who present years later with heart
failure, with or without ventricular arrhythmias, and are incorrectly diagnosed as having
idiopathic dilated cardiomyopathy.5 The diagnosis of ACM is based on the 2010 Task Force
Criteria (TFC), which include repolarization abnormalities, depolarization abnormalities,
arrhythmias, tissue characterization, structural abnormalities, and family history. However,
there is no agreed gold-standard, and limitations of the Task Force Criteria are: a) the
sentinel event can be SCD, with very subtle morphological abnormalities, which may not be
identified at post-mortem examination b) Electrical abnormalities can precede the structural
abnormalities, which can be easily missed. This has a huge impact on family members, as they
do not undergo appropriate clinical or genetic testing - missing an opportunity to intervene
and save lives c) Disease expression in the pediatric population is uncommon d) the long list
of criteria and modalities in the TFC make diagnosing ACM complex and time-consuming.
Identifying novel gene mutations in ACM may help in further understanding the pathogenesis of
the disease and may help in finding a new pharmacological target for such patients.
i. Design of the study Prospective, cohort study
ii. Inclusion and exclusion criteria
Inclusion criteria:
Patients diagnosed with ACM according to 2010 Task Force Criteria Parents of ACM patients
Siblings of ACM patients Relatives of ACM patients who have suffered an SCD
Exclusion criteria:
ACM patients or their relatives refuse to give consent for participation in the study. Study
subjects who refuse to provide consent for a specific test or investigation will not be
excluded.
iii. Endpoints:
1. Patients: Completion of the following data collection of all the patients:
ECG, Holter, Echocardiography, cardiac MRI, Endocardial voltage mapping, genetic
analysis along with blood and buccal samples for genetic analysis
2. Parents/siblings: Completion of the following data of all the parents, siblings: ECG,
Echocardiography along with blood and buccal samples for genetic analysis
3. SCD affected relatives of ACM patients: Completion of the following data of the affected
relatives: ECG, Holter, Echocardiography, cardiac MRI along with blood and buccal
samples for genetic analysis.
